# US 2004/0082527 A1 · Crystal forms of azithromycin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082527 A1
- Document ID: US20040082527A1
- Status: Published application
- Kind: A1
- Application number: 10/652,655
- Filed: 2003-08-28
- Published: 2004-04-29
- Earliest claimed: 2001-05-22
- Assignees: Pfizer Inc.
- Inventors: Zheng J. Li; Andrew V. Trask
- Web page: https://patentgrep.com/patent/US20040082527A1

## CPC

- C07H 17/00: Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- A61K 9/1688: {resulting in pure drug agglomerate optionally containing up to 5% of excipient}
- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61P 31/04: Antibacterial agents
- A61P 33/00: Antiparasitic agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- C07H 17/08: Hetero rings containing eight or more ring members, e.g. erythromycins
- A61K 9/2813: {Inorganic compounds}
- A61K 9/2826: {Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to novel crystal forms of azithromycin, an antibiotic useful in the treatment of infections.

## Claims

### Claim 1

A crystalline form of azithromycin selected from the group consisting of forms D, E, substantially pure F, G, J, M substantially in the absence of azithromycin dihydrate, N, O, P, Q, and R.

### Claim 2 (depends on 1)

A crystalline form of azithromycin according to claim 1 wherein said form is form D.

### Claim 3 (depends on 2)

A crystalline form according to claim 2 wherein said form is characterized as containing 2-6% water and 3-12% cyclohexane by weight in a powder sample.

### Claim 4 (depends on 2)

A pharmaceutical composition comprising a crystalline form of azithromycin according to claim 2 and a pharmaceutically acceptable excipient.

### Claim 5 (depends on 2)

A crystalline form of azithromycin according to claim 2 wherein said form is further characterized as having a 13C solid state NMR spectrum comprising a plurality of peaks with chemical shifts of about 178.1 ppm, 103.9 ppm, 95.1 ppm, 84.2 ppm, 10.6 ppm, 9.0 ppm and 8.6 ppm.

### Claim 6 (depends on 1)

A crystalline form of azithromycin according to claim 1 wherein said form is form E.

### Claim 7 (depends on 6)

A pharmaceutical composition comprising a crystalline form of azithromycin according to claim 6 and a pharmaceutically acceptable excipient.

### Claim 8 (depends on 1)

A crystalline form of azithromycin according to claim 1 wherein said form is substantially pure form F.

### Claim 9 (depends on 8)

A crystalline form according to claim 8 wherein said form is characterized as containing 2-5% water and 1-5% ethanol by weight in a powder sample.

### Claim 10 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said form is further characterized as having a 13C solid state NMR spectrum comprising a plurality of peaks with chemical shifts of about 179.5 ppm, 178.6 ppm, 58.0 ppm, 17.2 ppm, 10.1 ppm 9.8 ppm, 9.3 ppm, 7.9 ppm and 6.6 ppm.

### Claim 11 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises more than 80% by weight of form F azithromycin.

### Claim 12 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 81% or more by weight of form F azithromycin.

### Claim 13 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 82% or more by weight of form F azithromycin.

### Claim 14 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 83% or more by weight of form F azithromycin.

### Claim 15 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 84% or more by weight of form F azithromycin.

### Claim 16 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 85% or more by weight of form F azithromycin.

### Claim 17 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 86% or more by weight of form F azithromycin.

### Claim 18 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 87% or more by weight of form F azithromycin.

### Claim 19 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 88% or more by weight of form F azithromycin.

### Claim 20 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 89% or more by weight of form F azithromycin.

### Claim 21 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 90% or more by weight of form F azithromycin.

### Claim 22 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 91% or more by weight of form F azithromycin.

### Claim 23 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 92% or more by weight of form F azithromycin.

### Claim 24 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 93% or more by weight of form F azithromycin.

### Claim 25 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 94% or more by weight of form F azithromycin.

### Claim 26 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 95% or more by weight of form F azithromycin.

### Claim 27 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 96% or more by weight of form F azithromycin.

### Claim 28 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 97% or more by weight of form F azithromycin.

### Claim 29 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 98% or more by weight of form F azithromycin.

### Claim 30 (depends on 8)

A crystalline form of azithromycin according to claim 8 wherein said azithromycin comprises 99% or more by weight of form F azithromycin.

### Claim 31 (depends on 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

A pharmaceutical composition comprising a crystalline form of azithromycin as in claim 8 or in one of claims 11-30 and a pharmaceutically acceptable excipient

### Claim 32 (depends on 1)

A crystalline form of azithromycin according to claim 1 wherein said form is form G.

### Claim 33 (depends on 1)

A crystalline form of azithromycin according to claim 1 wherein said form is substantially pure form G.

### Claim 34 (depends on 32, 33)

A crystalline form according to claim 32 or claim 33 wherein said form is characterized as containing 2-6% water and less than 1% organic solvent by weight in a powder sample.

### Claim 35 (depends on 32, 33)

A crystalline form of azithromycin according to claim 32 or claim 33 wherein said form is further characterized as having a 13C solid state NMR spectrum comprising a plurality of peaks with chemical shifts of about 179.5 ppm, 10.4 ppm, 9.9 ppm, 9.3 ppm, 7.6 ppm and 6.5 ppm.

### Claim 36 (depends on 32)

A crystalline form of azithromycin according to claim 32 wherein said azithromycin comprises more than 50% by weight of form G azithromycin.

### Claim 37 (depends on 32)

A crystalline form of azithromycin according to claim 32 wherein said azithromycin comprises 55% or more by weight of form G azithromycin.

### Claim 38 (depends on 32)

A crystalline form of azithromycin according to claim 32 wherein said azithromycin comprises 60% or more by weight of form G azithromycin.

### Claim 39 (depends on 32)

A crystalline form of azithromycin according to claim 32 wherein said azithromycin comprises 65% or more by weight of form G azithromycin.

### Claim 40 (depends on 32)

A crystalline form of azithromycin according to claim 32 wherein said azithromycin comprises 70% or more by weight of form G azithromycin.

### Claim 41 (depends on 32)

A crystalline form of azithromycin according to claim 32 wherein said azithromycin comprises 75% or more by weight of form G azithromycin.

### Claim 42 (depends on 32)

A crystalline form of azithromycin according to claim 32 wherein said azithromycin comprises 80% or more by weight of form G azithromycin.

### Claim 43 (depends on 32)

A crystalline form of azithromycin according to claim 32 wherein said azithromycin comprises 85% or more by weight of form G azithromycin.

### Claim 44 (depends on 32)

A crystalline form of azithromycin according to claim 32 wherein said azithromycin comprises 90% or more by weight of form G azithromycin.

### Claim 45 (depends on 32)

A crystalline form of azithromycin according to claim 32 wherein said azithromycin comprises 91% or more by weight of form G azithromycin.

### Claim 46 (depends on 32)

A crystalline form of azithromycin according to claim 32 wherein said azithromycin comprises 92% or more by weight of form G azithromycin.

### Claim 47 (depends on 32)

A crystalline form of azithromycin according to claim 32 wherein said azithromycin comprises 93% or more by weight of form G azithromycin.

### Claim 48 (depends on 32)

A crystalline form of azithromycin according to claim 32 wherein said azithromycin comprises 94% or more by weight of form G azithromycin.

### Claim 49 (depends on 32)

A crystalline form of azithromycin according to claim 32 wherein said azithromycin comprises 95% or more by weight of form G azithromycin.

### Claim 50 (depends on 32)

A crystalline form of azithromycin according to claim 32 wherein said azithromycin comprises 96% or more by weight of form G azithromycin.

### Claim 51 (depends on 32)

A crystalline form of azithromycin according to claim 32 wherein said azithromycin comprises 97% or more by weight of form G azithromycin.

### Claim 52 (depends on 32)

A crystalline form of azithromycin according to claim 32 wherein said azithromycin comprises 98% or more by weight of form G azithromycin.

### Claim 53 (depends on 32)

A crystalline form of azithromycin according to claim 32 wherein said azithromycin comprises 99% or more by weight of form G azithromycin.

### Claim 54 (depends on 32, 33, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

A pharmaceutical composition comprising a crystalline form of azithromycin according to claim 32 or claim 33 or one of claims 36-53 and a pharmaceutically acceptable excipient

### Claim 55 (depends on 1)

A crystalline form according to claim 1 wherein said form is form H.

### Claim 56 (depends on 55)

A crystalline form of azithromycin according to claim 55 wherein said form is further characterized as having a 13C solid state NMR spectrum comprising a plurality of peaks with chemical shifts of about 179.5 ppm, 178.7 ppm, 9.9 ppm, 9.1 ppm, 7.9 ppm and 7.0 ppm.

### Claim 57 (depends on 55)

A pharmaceutical composition comprising a crystalline form of azithromycin according to claim 55 and a pharmaceutically acceptable excipient

### Claim 58 (depends on 1)

A crystalline form according to claim 1 wherein said form is form J.

### Claim 59 (depends on 58)

A crystalline form according to claim 58 wherein said form is characterized as containing 2-5% water and 1-5% n-propanol by weight in a powder sample.

### Claim 60 (depends on 58)

A crystalline form according to claim 58 wherein said form is further characterized as having a 13C solid state NMR spectrum comprising a plurality of peaks with chemical shifts of about 179.6 ppm, 178.4 ppm, 25.2 ppm, 11.5 ppm, 10.0 ppm, 9.3 ppm, 8.1 ppm and 6.8 ppm.

### Claim 61 (depends on 58)

A pharmaceutical composition comprising a crystalline form of azithromycin according to claim 58 and a pharmaceutically acceptable excipient.

### Claim 62 (depends on 1)

A crystalline form according to claim 1 wherein said form is form M substantially in the absence of azithromycin dihydrate.

### Claim 63 (depends on 62)

A crystalline form according to claim 62 wherein said form is characterized as containing 2-5% water and 1-7% 2-propanol by weight in a powder sample.

### Claim 64 (depends on 62)

A crystalline form according to claim 62 wherein said form is further characterized as having a 13C solid state NMR spectrum comprising a plurality of peaks with chemical shifts of about 179.6 ppm, 41.9, 26.0 ppm, 16.3 ppm, 10.3 ppm, 9.6 ppm, 9.3 ppm, 7.7 ppm and 7.1 ppm.

### Claim 65 (depends on 62)

A crystalline form of azithromycin according to claim 62 wherein said azithromycin comprises less than 5% by weight of azithromycin dihydrate.

### Claim 66 (depends on 62)

A crystalline form of azithromycin according to claim 62 wherein said azithromycin comprises less than 4% by weight of azithromycin dihydrate.

### Claim 67 (depends on 62)

A crystalline form of azithromycin according to claim 62 wherein said azithromycin comprises less than 3% by weight of azithromycin dihydrate.

### Claim 68 (depends on 62)

A crystalline form of azithromycin according to claim 62 wherein said azithromycin comprises less than 2% by weight of azithromycin dihydrate.

### Claim 69 (depends on 62)

A crystalline form of azithromycin according to claim 62 wherein said azithromycin comprises less than 1% by weight of azithromycin dihydrate.

### Claim 70 (depends on 62, 63, 64, 65, 66, 67, 68, 69)

A pharmaceutical composition comprising a crystalline form of azithromycin according to one of claims 62-69 and a pharmaceutically acceptable excipient.

### Claim 71 (depends on 1)

A crystalline form according to claim 1 wherein said form is form N.

### Claim 72 (depends on 71)

A crystalline form according to claim 71 wherein said form is characterized as containing 1-5% water and 2-5% organic solvent by weight in a powder sample.

### Claim 73 (depends on 71)

A crystalline form according to claim 71 wherein said form is further characterized as having a 13C solid state NMR spectrum comprising a plurality of peaks with chemical shifts of about 179.6 ppm, 178.7 ppm, 58.1 ppm, 26.0 ppm, 9.9 ppm, 9.4 ppm, 7.9 ppm, and 6.6 ppm.

### Claim 74 (depends on 71, 72, 73)

A pharmaceutical composition comprising a crystalline form of azithromycin according to one of claims 71-73 and a pharmaceutically acceptable excipient.

### Claim 75 (depends on 1)

A crystalline form according to claim 1 wherein said form is form O.

### Claim 76 (depends on 75)

A pharmaceutical composition comprising a crystalline form of azithromycin according to claim 75 and a pharmaceutically acceptable excipient.

### Claim 77 (depends on 1)

A crystalline form according to claim 1 wherein said form is form P.

### Claim 78 (depends on 87)

A pharmaceutical composition comprising a crystalline form of azithromycin according to claim 87 and a pharmaceutically acceptable excipient.

### Claim 79 (depends on 1)

A crystalline form according to claim 1 wherein said form is form Q.

### Claim 80 (depends on 79)

A pharmaceutical composition comprising a crystalline form of azithromycin according to claim 79 and a pharmaceutically acceptable excipient.

### Claim 81 (depends on 1)

A crystalline form according to claim 1 wherein said form is form R.

### Claim 82 (depends on 81)

A crystalline form according to claim 81 wherein said form is further characterized as having a 13C solid state NMR spectrum having a plurality of peaks with chemical shifts of about 177.9 ppm, 95.3 ppm, 10.3 ppm, 9.6 ppm, 8.9 ppm, and 8.6 ppm.

### Claim 83 (depends on 81, 82)

A pharmaceutical composition comprising a crystalline form of azithromycin according to claim 81 or 82 and a pharmaceutically acceptable excipient.

### Claim 84

An azithromycin mixture comprising azithromycin dihydrate and one or more hydrate/solvates of azithromycin or azithromycin sesquhydrate.

### Claim 85 (depends on 84)

An azithromycin mixture according to claim 84 wherein the hydrate/solvate contains a solvent selected from the group consisting of ethanol, 2-propanol, n-propanol, formic acid, butanol, pentanol, tetrahydrofuran, propylene glycol, acetone, cyclohexane, and acetonitrile

### Claim 86

An azithromycin mixture comprising azithromycin dihydrate and one or more forms of azithromycin selected from the group consisting of form D, form F, form G, form H, form J, form M, form O, form Q and form R.

### Claim 87 (depends on 86)

An azithromycin mixture according to claim 86 comprising form A and form F.

### Claim 88 (depends on 86)

An azithromycin mixture according to claim 86 comprising form A and form G.

### Claim 89 (depends on 86)

An azithromycin mixture according to claim 86 comprising form A and form H.

### Claim 90 (depends on 86)

An azithromycin mixture according to claim 86 comprising form A and form J.

### Claim 91 (depends on 86)

An azithromycin mixture according to claim 86 comprising form A and form M.

### Claim 92 (depends on 86)

An azithromycin mixture according to claim 86 comprising form A and form F and form G.

### Claim 93 (depends on 86)

An azithromycin mixture according to claim 86 comprising form A and form G and form M.

### Claim 94

A family of azithromycin crystalline forms wherein said family is Family II.

### Claim 95 (depends on 64)

The family of claim 64 wherein said family is characterized as belonging to an orthorhombic P212121 space group with cell dimensions of a=8.8±0.4 Å, b=12.3±0.5 Å and c=45±0.5 Å.

### Claim 96 (depends on 2)

A method of preparing the crystalline form of claim 2 comprising the step of slurrying azithromycin with cyclohexane and isolating crystalline azithromycin.

### Claim 97 (depends on 8)

A method of preparing the crystalline form of claim 8 comprising the steps of dissolving azithromycin in ethanol to form an ethanol solution, cooling the ethanol solution to below 20° C., precipitating azithromycin crystals and isolating the crystals.

### Claim 98 (depends on 97)

A method according to claim 97 wherein the ethanol solution is cooled to 15° C. or below.

### Claim 99 (depends on 97)

A method according to claim 97 wherein the ethanol solution is cooled to 10° C. or below.

### Claim 100 (depends on 97)

A method according to claim 97 wherein the ethanol solution is cooled to 5° C. or below.

### Claim 101 (depends on 97, 98, 99, 100)

A method as in one of claims 97-100 further comprising the step of adding water to the ethanol solution after the ethanol solution has been cooled.

### Claim 102 (depends on 101)

A method according to claim 101 further comprising the step of cooling the water prior to adding the water to the ethanol solution.

### Claim 103 (depends on 102)

A method according to claim 102 wherein the water is cooled to below 20° C.

### Claim 104 (depends on 102)

A method according to claim 102 wherein the water is cooled to 15° C. or below.

### Claim 105 (depends on 102)

A method according to claim 102 wherein the water is cooled to 10° C. or below.

### Claim 106 (depends on 102)

A method according to claim 102 wherein the water is cooled to 5° C. or below.

### Claim 107 (depends on 97, 98, 99, 100)

A method according to one of claims 97 to 100 further comprising the step of seeding the cooled ethanol solution with crystals of form F azithromycin.

### Claim 108 (depends on 32)

A method of preparing the crystalline form of claim 32 comprising the steps of dissolving azithromycin in a 1:1 mixture of water and a solvent that is a member selected from the group consisting of methanol, acetone, acetonitrile, adding water to the mixture, precipitating azithromycin crystals and isolating the crystals.

### Claim 109 (depends on 58)

A method of preparing the crystalline form of claim 58 comprising the steps of dissolving azithromycin in n-propanol, adding water, precipitating azithromycin crystals and isolating the crystals.

### Claim 110 (depends on 62)

A method of preparing the crystalline form of claim 62 comprising the steps of dissolving azithromycin with isopropanol to form an isopropanol solution, cooling the isopropanol solution to below 15° C., adding water after the isopropanol solution has been cooled, precipitating azithromycin crystals and isolating the crystals.

### Claim 111 (depends on 110)

A method according to claim 110 wherein the isopropanol solution is cooled to 10° C. or below.

### Claim 112 (depends on 110)

A method according to claim 110 wherein the isopropanol solution is cooled to 5° C. or below.

### Claim 113 (depends on 110, 111, 112)

A method according to one of claims 110 to 112 wherein the water is cooled prior to adding the water to the isopropanol solution.

### Claim 114 (depends on 113)

A method according to claim 113 wherein the water is cooled to 20° C. or below.

### Claim 115 (depends on 113)

A method according to claim 113 wherein the water is cooled to 15° C. or below.

### Claim 116 (depends on 113)

A method according to claim 113 wherein the water is cooled to 10° C. or below.

### Claim 117 (depends on 113)

A method according to claim 113 wherein the water is cooled to 5° C. or below.

### Claim 118 (depends on 110)

A method according to claim 110 wherein the crystals are isolated within 5 hours of precipitation.

### Claim 119 (depends on 110)

A method according to claim 110 wherein the crystals are isolated within 3 hours of precipitation.

### Claim 120 (depends on 110)

A method according to claim 110 wherein the crystals are isolated within 1 hour of precipitation.

### Claim 121 (depends on 110)

A method according to claim 110 wherein the crystals are isolated within 30 minutes of precipitation.

### Claim 122 (depends on 62, 110, 111, 112)

A method according to one of claims claim 110 to 112 further comprising the step of seeding the cooled isopropanol solution with crystals of the crystalline form of claim 62.

### Claim 123 (depends on 1, 86)

A method of treating a bacterial infection or a protozoa infection in a mammal, fish, or bird which comprises administering to said mammal, fish or bird a therapeutically effective amount of crystalline azithromycin according to claim 1 or an azithromycin mixture according to claim 86.
